Johnson & Johnson (JNJ)
Summary
JNJ Chart
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE) SPRING HOUSE, Pa. , April 30, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG).
3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
In a market where investors are increasingly seeking stability and reliable returns, several industry giants have stepped up with significant dividend increases. Johnson & Johnson NYSE: JNJ, Costco Wholesale NASDAQ: COST, and NASDAQ NASDAQ: NDAQ have each announced meaningful hikes to their quarterly payouts, reinforcing their commitment to shareholder value even amid broader market volatility.
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing.
Johnson & Johnson Dividends
| JNJ 2 months ago | Other | €1.09 Per Share |
| JNJ 5 months ago | Other | €1.09 Per Share |
| JNJ 8 months ago | Other | €1.09 Per Share |
| JNJ 11 months ago | Other | €1.09 Per Share |
| JNJ 16 Feb 2024 | Other | €1.05 Per Share |
Johnson & Johnson Earnings
| 15 Apr 2025 Date | | - Cons. EPS | - EPS |
| 14 Apr 2025 Date | | - Cons. EPS | - EPS |
| 21 Jan 2025 Date | | - Cons. EPS | - EPS |
| 15 Oct 2024 Date | | - Cons. EPS | - EPS |
| 17 Jul 2024 Date | | - Cons. EPS | - EPS |
| JNJ 2 months ago | Other | €1.09 Per Share |
| JNJ 5 months ago | Other | €1.09 Per Share |
| JNJ 8 months ago | Other | €1.09 Per Share |
| JNJ 11 months ago | Other | €1.09 Per Share |
| JNJ 16 Feb 2024 | Other | €1.05 Per Share |
| 15 Apr 2025 Date | | - Cons. EPS | - EPS |
| 14 Apr 2025 Date | | - Cons. EPS | - EPS |
| 21 Jan 2025 Date | | - Cons. EPS | - EPS |
| 15 Oct 2024 Date | | - Cons. EPS | - EPS |
| 17 Jul 2024 Date | | - Cons. EPS | - EPS |
Johnson & Johnson (JNJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Johnson & Johnson ever had a stock split?
Johnson & Johnson Profile
| Engineering & Construction Industry | Industrials Sector | Mr. Roberto Cecatto CEO | XMUN Exchange | US4781601046 ISIN |
| Italy Country | 600 Employees | 18 Feb 2025 Last Dividend | 13 Jun 2001 Last Split | - IPO Date |
Overview
Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.
Products and Services
The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:
- Innovative Medicine:
This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.
- MedTech:
This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.
Contact Information
